Literature DB >> 25559235

Repeated Hepatic Resection versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Hepatic Resection: A Propensity Score Matching Study.

Kyoung Doo Song1, Hyo Keun Lim, Hyunchul Rhim, Min Woo Lee, Young-Sun Kim, Won Jae Lee, Yong Han Paik, Geum-Youn Gwak, Jong Man Kim, Choon Hyuck David Kwon, Jae-Won Joh.   

Abstract

PURPOSE: To compare the long-term outcomes of repeated hepatic resection and radiofrequency (RF) ablation for recurrent hepatocellular carcinoma (HCC) by using propensity score matching.
MATERIALS AND METHODS: This retrospective study was approved by the institutional review board, and the requirement to obtain informed consent was waived. Thirty-nine patients who underwent repeated hepatic resection and 178 who underwent RF ablation for recurrent HCC (mean tumor size ± standard deviation, 1.8 cm ± 0.7) between November 1994 and December 2012 were included in the study. Patients ranged in age from 24 to 85 years (mean, 54.9 years). Men ranged in age from 25 to 85 years (mean, 54.8 years), and women ranged in age from 24 to 76 years (mean, 55.4 years). A 1:2 repeated hepatic resection group-RF ablation group matching was done by using propensity score matching. The overall survival (OS) and disease-free survival (DFS) were compared before and after propensity score matching. Complications were assessed.
RESULTS: Before matching, OS rates at 1, 3, 5, and 8 years were 88.8%, 88.8%, 83.9%, and 56.3%, respectively, with repeated hepatic resection and 98.9%, 82.5%, 71.0%, and 58.3% for RF ablation. DFS rates at 1, 3, and 5 years were 66.1%, 48.5%, and 43.1% for repeated hepatic resection and 70.1%, 40.8%, and 30.0% for RF ablation. After matching, the OS rates at 1, 3, 5, and 8 years were 98.7%, 85.7%, 72.1%, and 68.6%, respectively, and the DFS rates at 1, 3, and 5 years were 71.8%, 45.1%, and 39.4% in the RF ablation group (n = 78). Neither the OS nor DFS rate was significantly different between the two groups before matching (P = .686 and P = .461) and after matching (P = .834 and P = .960). The postoperative mortality rate was 2.6% in the repeated hepatic resection group and 0% in the RF ablation group.
CONCLUSION: The long-term OS and DFS were not significantly different between repeated hepatic resection and RF ablation for patients with recurrent HCC after hepatic resection. (©) RSNA, 2015.

Entities:  

Mesh:

Year:  2015        PMID: 25559235     DOI: 10.1148/radiol.14141568

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  24 in total

1.  Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.

Authors:  Zhenwei Peng; Mengchao Wei; Shuling Chen; Manxia Lin; Chunlin Jiang; Jie Mei; Bin Li; Yu Wang; Jiaping Li; Xiaoyan Xie; Ming Kuang
Journal:  Eur Radiol       Date:  2018-03-13       Impact factor: 5.315

2.  Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma.

Authors:  Junichi Shindoh; Yusuke Kawamura; Yuta Kobayashi; Norio Akuta; Masahiro Kobayashi; Yoshiyuki Suzuki; Kenji Ikeda; Masaji Hashimoto
Journal:  J Gastrointest Surg       Date:  2019-06-12       Impact factor: 3.452

3.  Liver Resection Versus Embolization for Recurrent Hepatocellular Carcinoma.

Authors:  Yutaka Midorikawa; Tadatoshi Takayama; Masamichi Moriguchi; Rempei Yagi; Shunsuke Yamagishi; Hisashi Nakayama; Osamu Aramaki; Shintaro Yamazaki; Shingo Tsuji; Tokio Higaki
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

4.  Treatment and outcomes of recurrent hepatocellular carcinomas.

Authors:  Gaëtan-Romain Joliat; Pierre Allemann; Ismail Labgaa; Nicolas Demartines; Nermin Halkic
Journal:  Langenbecks Arch Surg       Date:  2017-05-11       Impact factor: 3.445

Review 5.  Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.

Authors:  Maria Tampaki; George Vasileios Papatheodoridis; Evangelos Cholongitas
Journal:  Clin J Gastroenterol       Date:  2021-03-27

Review 6.  Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function.

Authors:  Taro Takami; Takahiro Yamasaki; Issei Saeki; Toshihiko Matsumoto; Yutaka Suehiro; Isao Sakaida
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

7.  Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications.

Authors:  Ran Kim; Tae Wook Kang; Dong Ik Cha; Kyoung Doo Song; Min Woo Lee; Hyunchul Rhim; Hyo Keun Lim; Dong Hyun Sinn
Journal:  Eur Radiol       Date:  2018-07-24       Impact factor: 5.315

8.  Comparison of the safety and efficacy of hepatic resection and radiofrequency ablation in the treatment of single small hepatocellular carcinoma: systematic review and meta-analysis.

Authors:  Ke Wang; Rui Wang; Siqin Liu; Guoqing Peng; Huan Yu; Xiaomei Wang
Journal:  Transl Cancer Res       Date:  2022-03       Impact factor: 1.241

9.  Quality of Life and Cost-Effectiveness of Radiofrequency Ablation versus Open Surgery for Benign Thyroid Nodules: a retrospective cohort study.

Authors:  Wen-Wen Yue; Shu-Rong Wang; Xiao-Long Li; Hui-Xiong Xu; Feng Lu; Li-Ping Sun; Le-Hang Guo; Ya-Ping He; Dan Wang; Zhi-Qiang Yin
Journal:  Sci Rep       Date:  2016-11-24       Impact factor: 4.379

10.  Treatment of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma.

Authors:  Michinori Matsumoto; Katsuhiko Yanaga; Hiroaki Shiba; Shigeki Wakiyama; Taro Sakamoto; Yasuro Futagawa; Takeshi Gocho; Yuichi Ishida; Toru Ikegami
Journal:  Ann Gastroenterol Surg       Date:  2021-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.